Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Veracyte (VCYT) Research & Development (2016 - 2025)

Veracyte's Research & Development history spans 14 years, with the latest figure at $20.8 million for Q4 2025.

  • For Q4 2025, Research & Development rose 8.08% year-over-year to $20.8 million; the TTM value through Dec 2025 reached $70.8 million, up 2.19%, while the annual FY2025 figure was $70.8 million, 2.19% up from the prior year.
  • Research & Development for Q4 2025 was $20.8 million at Veracyte, up from $16.0 million in the prior quarter.
  • Across five years, Research & Development topped out at $20.8 million in Q4 2025 and bottomed at $5.3 million in Q1 2021.
  • The 5-year median for Research & Development is $13.0 million (2023), against an average of $13.4 million.
  • The largest annual shift saw Research & Development soared 123.55% in 2021 before it dropped 9.06% in 2025.
  • A 5-year view of Research & Development shows it stood at $10.3 million in 2021, then grew by 10.1% to $11.3 million in 2022, then surged by 65.44% to $18.7 million in 2023, then increased by 3.3% to $19.3 million in 2024, then grew by 8.08% to $20.8 million in 2025.
  • Per Business Quant, the three most recent readings for VCYT's Research & Development are $20.8 million (Q4 2025), $16.0 million (Q3 2025), and $16.3 million (Q2 2025).